<?xml version='1.0' encoding='utf-8'?>
<document id="29761830"><sentence text="ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision."><entity charOffset="18-27" id="DDI-PubMed.29761830.s1.e0" text="Metformin" /></sentence><sentence text="Metformin drug-drug interaction (DDI) studies are conducted during development of drugs that inhibit organic cation transporters and/or multidrug and toxin extrusion proteins (OCTs/MATEs)"><entity charOffset="0-9" id="DDI-PubMed.29761830.s2.e0" text="Metformin" /></sentence><sentence text=" Monitoring solely changes in systemic exposure, the typical DDI study endpoint appears inadequate for metformin, which is metabolically stable, has poor passive membrane permeability, and undergoes transporter-mediated tissue distribution and clearance"><entity charOffset="103-112" id="DDI-PubMed.29761830.s3.e0" text="metformin" /></sentence><sentence text=" Evaluation of renal clearance, antihyperglycemic effects, and potentially lactate as an exploratory safety marker, can support rational metformin dose adjustment"><entity charOffset="75-82" id="DDI-PubMed.29761830.s4.e0" text="lactate" /><entity charOffset="137-146" id="DDI-PubMed.29761830.s4.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.29761830.s4.e0" e2="DDI-PubMed.29761830.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29761830.s4.e0" e2="DDI-PubMed.29761830.s4.e1" /></sentence><sentence text=" The proposed DDI study design aims to adequately inform metformin dosing during comedication"><entity charOffset="57-66" id="DDI-PubMed.29761830.s5.e0" text="metformin" /></sentence><sentence text="" /></document>